JP2016513647A5 - - Google Patents

Download PDF

Info

Publication number
JP2016513647A5
JP2016513647A5 JP2016502054A JP2016502054A JP2016513647A5 JP 2016513647 A5 JP2016513647 A5 JP 2016513647A5 JP 2016502054 A JP2016502054 A JP 2016502054A JP 2016502054 A JP2016502054 A JP 2016502054A JP 2016513647 A5 JP2016513647 A5 JP 2016513647A5
Authority
JP
Japan
Prior art keywords
composition
bimatoprost
administered
composition according
reducing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016502054A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016513647A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/026110 external-priority patent/WO2014143629A1/en
Publication of JP2016513647A publication Critical patent/JP2016513647A/ja
Publication of JP2016513647A5 publication Critical patent/JP2016513647A5/ja
Pending legal-status Critical Current

Links

JP2016502054A 2013-03-15 2014-03-13 レプチン生産を増進するビマトプロスト Pending JP2016513647A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361793132P 2013-03-15 2013-03-15
US61/793,132 2013-03-15
PCT/US2014/026110 WO2014143629A1 (en) 2013-03-15 2014-03-13 Bimatoprost for enhancement of leptin production

Publications (2)

Publication Number Publication Date
JP2016513647A JP2016513647A (ja) 2016-05-16
JP2016513647A5 true JP2016513647A5 (https=) 2017-04-13

Family

ID=50442712

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016502054A Pending JP2016513647A (ja) 2013-03-15 2014-03-13 レプチン生産を増進するビマトプロスト

Country Status (11)

Country Link
US (2) US20140275272A1 (https=)
EP (1) EP2968361A1 (https=)
JP (1) JP2016513647A (https=)
KR (1) KR20150129735A (https=)
CN (1) CN105338985A (https=)
AU (1) AU2014228307A1 (https=)
BR (1) BR112015021859A2 (https=)
CA (1) CA2901529A1 (https=)
HK (1) HK1220385A1 (https=)
RU (1) RU2015134772A (https=)
WO (1) WO2014143629A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016176640A1 (en) 2015-04-30 2016-11-03 Allergan, Inc. Cosmetic method and therapeutic use for fat reduction

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
ATE141502T1 (de) 1991-01-15 1996-09-15 Alcon Lab Inc Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US5688819A (en) 1992-09-21 1997-11-18 Allergan Cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US7666912B2 (en) * 2006-03-23 2010-02-23 Massachusetts Eye And Ear Infirmary Compositions and methods for reducing body fat
CA2749352A1 (en) * 2009-02-20 2010-09-10 Micro Labs Limited Storage stable prostaglandin product
ES2687494T3 (es) * 2011-01-19 2018-10-25 Topokine Therapeutics, Inc. Métodos y composiciones para reducir la grasa corporal

Similar Documents

Publication Publication Date Title
MX377629B (es) Composiciones farmacéuticas tópicas.
JP2014505733A5 (https=)
BR112014010275A2 (pt) formulações para tratamento de diabetes
MX2022009595A (es) Sales de berberina, sales ursodesoxicolicas y combinaciones, metodos de preparacion y aplicacion de las mismas.
WO2017022962A8 (ko) Ripk 억제제를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물
RU2013141845A (ru) Фармацевтическая композиция в виде крема, содержащая оксиметазолин, для лечения симптомов розацеа
HRP20171648T1 (hr) Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze
MY189770A (en) Biaryl derivative as gpr120 agonists
MX381039B (es) Composiciones basadas en metil ciclodextrinas para el tratamiento y/o prevención de enfermedades aumentando el nivel de colesterol hdl.
EP4410833A3 (en) Compositions and methods for treating fatty tissue buildup
JP2015535214A5 (https=)
EP4219714A3 (en) Rna interference mediated inhibition of tmprss6
FR3024037B1 (fr) Ingredient actif cosmetique ou dermatologique comprenant un melange d'acides dicarboxyliques gras insatures, compositions le comprenant et utilisations cosmetiques ou dermatologiques
MX378007B (es) Derivados de biarilo como agonistas de gpr120.
WO2012050831A3 (en) Combination treatment for dermatological conditions
WO2014107730A3 (en) Use of fatty acid niacin conjugates for treating diseases
WO2015038552A3 (en) Aspirin formulation for increased efficacy
ATE522224T1 (de) Medizinisches kräuterextrakt mit wirkung gegen adipositas
MY160377A (en) Topical pharmaceutical compositions
PE20150345A1 (es) Nuevo compuesto que tiene la capacidad para inhibir la enzima deshidrogenasa 11b-hidroxiesteroide tipo 1 (11b-hsd1) o sal farmaceuticamente aceptable del mismo, metodo para producir el mismo, y composicion farmaceutica que contiene el mismo como ingrediente activo
WO2015121457A8 (en) Fgf-8 for use in treating diseases or disorders of energy homeostasis
JP2018536638A5 (https=)
JP2019529569A5 (https=)
JP2016513647A5 (https=)
EA201590825A1 (ru) Способы контролирования кровяного давления и снижения диспноэ при сердечной недостаточности